ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

PDF) Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

The proportions of patients in ASAS20 response (A), ASAS40 response

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy

Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Baseline characteristics of patients included in the two treatment arms

Changes from baseline in ASDAS and BASFI over time. Dashed line: all

Baseline characteristics of ASDAS ID and ASAS PR responders and

ASDAS calculator - ASAS

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Frontiers Targeted Therapies in Axial Psoriatic Arthritis